Filed July 2003, very simple because it was written
for lawyers ;)
On the following, correct to 15% of the population, not 30% as Steere said:
ORIGINAL WEBPAGE BUILT IN 2003:
PAGE 4 of
the Complaint
Pages 1,2 =
DOJ Form
Page 3, 4 =
Western Blots
Entities
involved:
Yale
University, Patent for rOspA = LymeRIX
vaccine, Apparent alliance with
CastleConnolly.com, on Tick-Borne
diseases.
Connaught,
(now Aventis) Patent for OspA = ImmuLyme
vaccine
Glaxo
SmithKline, ran Yale’s Patented
vaccine
Corixa,
Washington, State
Imugen,
Norwood, Mass.
Alan
Barbour, Louis
Magnarelli (we’re not naming
Magnarelli), Sven Bergstrom, Patent for
OspA, for Connaught’s ImmuLyme
Sven
Bergstrom (EUCALB ADVISOR)
David Persing formerly of
Mayo, now at Corixa, Patent for
OspA-less Borrelia, and licensed to
Imugen and L2 Diagnostics (Yale
spinoff)
John
Connolly (CastleConnolly.com)
Arthur
Weinstein, NYMC and Georgetown
(Spinning what is Chromatography, and
what is Fibromyalgia, His
validations and methods are nonsense.
"The
College has recognized that Lyme disease
is a major clinical and research
interest on this campus. The main
players in the development of the
program were Fish, Wormser and
Connolly," Dr. Weinstein advises. The
entrepreneurial trio are Durland Fish,
Ph.D., former director of the College's
Lyme Disease Center and now a research
scientist at Yale; Gary P. Wormser,
M.D., still professor of medicine and
pharmacology and chief of the Division
of Infectious Diseases at the College;
and John J. Connolly, Ed.D., former
College president and current chairman
of the board of the American Lyme
Disease Foundation, Inc., which had its
genesis on the Valhalla campus in 1990.
http://www.nymc.edu/intouch/spr98/lyme.htm
Leonard Sigal, formerly of
Robert Woods Johnson and UDMNJ
See my website. His contribution
to this problem is enormous
Munchausen’s accusations, etc
http://www.actionlyme.com/Sigal.htm
Allen
Steere, Harvard (formerly of Yale,
then Tufts)
Mark
Klempner, Boston University,
(Formerly of Tufts, New England Medical
Center, which is
affiliated with LifeSpan “@partners.org”,
no doubt the result of CastleConnolly’s
influence upon HMOs.)
Eugene
Shapiro, Yale Pediatric Infectious
Disease
Robert
Schoen, Yale Rheumatology
Janine
Evans, Yale Rheumatology
Vijay Sikand,
Private practice, East Lyme, CT.
Phillip
Molloy, Imugen, Medical Director.
Erol
Fikrig, Yale – OspA patent
Durland
Fish—NYMC, and now at Yale Vector
Biology Lab
Gary
Wormser-- NYMC
Robert
Nadelman-- NYMC
John
Nowakowski-- NYMC
Barbara
Johnson, CDC, Fort Collins
Edward
McSweegan, NIH
Dave
Dennis, Formerly of the CDC, now
retired
OVERVIEW
OF THE ORGANIZATION:
Lyme is
incurable, and tick borne
diseases were recognized to be an industry, as said above in the
Weinstein article, by John Connolly and
Company (the ALDF).
It was
not possible to have a vaccine for Lyme
disease, due to antigenic
variation/changing bands/ different
strains and species of Borrelia.
The CDC
had a standard for the bloodwork
diagnosis (serodiagnosis) of Lyme
disease. The standard was what
represented, essentially, the changing
bands, etc. (1990)
Then
the “Organization” changed that standard
to falsely qualify a vaccine.
This
was known as the “Dressler/Steere”
Standard.
This false
standard, was adopted for use, by the
FDA, but we don’t know how à
That being the crux of the RICO case.
Corixa,
Glaxo- SmithKline, Imugen, and Pasteur/Aventis
Connaught, are formally business
partners. L2 diagnostics and
Imugen have exclusive rights to Corixa’s
Dave Persing’s OspA-less bug patent to
test for Lyme disease after the vaccines
were on the market.
ALDF.com,
EUCALB, CastleConnolly.com, Yale
and L2 Diagnostics, which are two
things: So-called Non-profits,
Yale, a Private Corporation, and a
Biotech SpinOff, created for spinning
disease definitions in both treatment
and vaccines, and test kits.
THIS is
actually Lyme borreliosis:
http://www.jstd.org/abstracts/v3n1_96.html
The Borrelia turicatae murine
model of Lyme disease
Alan G. Barbour, MD. JSTD 1996;
3:62-66.
Borrelia turicatae is
an agent of relapsing fever. During
relapsing fever spirochetes avoid the
immune response of the host by a
multiphasic antigenic variation. In Borrelia hermsii, another agent of
relapsing fever, the mechanism for the
switch in antigens is a gene
rearrangement, namely an interplasmidic
gene conversion or an intraplasmidic
deletion between direct repeats. In
severe combined immunodeficiency (scid)
mice, B. turicatae causes the
constellation of arthritis, myocarditis,
uveitis, and a cranial nerve disorder.
In this way, the infection in these mice
is similar to Lyme disease. Moreover, B. turicatae invades and persists in
the central nervous system of laboratory
mice. The severity of illness,
particularly the arthritis, and the
entry into the brain appear to be
determined by the small Vmp proteins of
this species. These proteins are
homologous to the polymorphic OspC
proteins of B. burgdorferi, the
agent of Lyme disease.
Permanent
brain infection
|
J
Infect Dis 1993 Jul;168(1):143-51 |
|
Experimental infection of the mouse
brain by a relapsing fever Borrelia
species: a molecular analysis.
Cadavid D, Bundoc V, Barbour AG.
Department of Microbiology, University
of Texas Health Science Center, San
Antonio 78284-7758.
The spirochetal disease relapsing fever
is notable not only for multiphasic
antigenic variation but also for central
neurologic manifestations. To further
characterize involvement of the brain in
this disorder, immunocompetent and
-deficient mice were infected with
Borrelia hermsii. Immunodeficient mice
were treated while spirochetemic with
neutralizing IgM monoclonal antibodies
to the infecting serotype. Blood,
cerebrospinal fluid, and brain tissue
were examined by culture and polymerase
chain reaction. In immunocompetent mice,
antigenic variation occurred in the
brain as well as in the blood. In
immunodeficient mice, the infecting
serotype was still present in the brain
after it had been eliminated from the
blood by the administered antibodies. These latter results cannot be accounted
for by contamination of brain tissue and
cerebrospinal fluid by blood and, hence,
establish the direct involvement of the
central nervous system in this
experimental infection. PMID:
8515101 [PubMed - indexed for MEDLINE]
|
Antimicrob Agents Chemother 1996
Nov;40(11):2632-6 |
|
In vivo
activities of ceftriaxone and vancomycin
against Borrelia spp. in the mouse brain
and other sites.
Kazragis RJ, Dever LL, Jorgensen JH,
Barbour AG.
Department of Medicine (Infectious
Diseases), University of Texas Health
Science Center at San Antonio 78284,
USA.
Borrelia burgdorferi, the agent of Lyme
disease, and B. turicatae, a neurotropic
agent of relapsing fever, are
susceptible to vancomycin in vitro, with
an MIC of 0.5 microgram/ml. To determine
the activity of vancomycin in vivo,
particularly in the brain, we infected
adult immunocompetent BALB/c and
immunodeficient CB-17 scid mice with B.
burgdorferi or B. turicatae. The mice
were then treated with vancomycin,
ceftriaxone as a positive control, or
normal saline as a negative control. The
effectiveness of treatment was assessed
by cultures of blood and brain and other
tissues. Ceftriaxone at a dose of 25
mg/kg of body weight administered every
12 h for 7 to 10 days eliminated
cultivable B. burgdorferi or B.
turicatae from all BALB/c or scid mice
in the study. Vancomycin at 30 mg/kg
administered every 12 h was effective in
eliminating infection from
immunodeficient mice if treatment was
started within 3 days of the onset of
infection. If treatment with vancomycin
was delayed for 7 days or more,
vancomycin failed to eradicate infection
with B. burgdorferi or B. turicatae from
immunodeficient mice. The failure of
vancomycin in eradicating established
infections in immunodeficient mice was
associated with the persistence of
viable spirochetes in the brain during
antibiotic treatment.
PMID: 8913478 [PubMed - indexed for
MEDLINE]
Antigenic
variation
|
Res
Microbiol 1991 Jul-Aug;142(6):711-7 |
|
Antigenic variation in Borrelia.
Saint Girons I, Barbour AG.
Unite des Leptospires, Institut Pasteur,
Paris.
Antigenic variation was demonstrated for
the agent of relapsing fever, Borrelia
hermsii. The phenomenon is correlated
with changes in major surface proteins
called Vmp. The genes encoding these
antigens are located on linear plasmids.
Expression occurs by transposition of
genes encoding Vmp to a telomeric
expression site located on another
linear plasmid. Activation of a vmp gene
occurs by placing it downstream from a
promoter. Resemblance to the
antigenic variation of trypanosomes is
discussed.
|
Emerg
Infect Dis 2000
Sep-Oct;6(5):449-57 |
|
Antigenic variation in vector-borne
pathogens.
Barbour AG, Restrepo BI.
University of California Irvine, Irvine,
California 92697-4025, USA. abarbour@uci.edu
Several pathogens of humans and domestic
animals depend on hematophagous
arthropods to transmit them from one
vertebrate reservoir host to another and
maintain them in an environment. These
pathogens use antigenic variation to
prolong their circulation in the blood
and thus increase the likelihood of
transmission. By convergent evolution,
bacterial and protozoal vector-borne
pathogens have acquired similar genetic
mechanisms for successful antigenic
variation. Borrelia spp. and Anaplasma
marginale (among bacteria) and African
trypanosomes, Plasmodium falciparum, and
Babesia bovis (among parasites) are
examples of pathogens using these
mechanisms. Antigenic variation poses
a challenge in the development of
vaccines against vector-borne pathogens.
CHRONOLOGY
1986, The
Biology of Borrelia Species—Alan Barbour
1986,
Antigenic variation, by Steere:
“This could be a chronic parasitic
infection” not knowing a THING about
spirochetes, apparently. THIS is
the real and original serodiagnostic
criteria. Adopted by CDC and
published in 1990.
1989 Infectious Disease Reviews.
This disease is serious and incurable.
1990, The American Lyme disease Foundation
was founded by/for Managed Care (John
Connolly, who then sold out New York
Medical College to Kaiser). Patent
holders and vaccine trial administrators
become members and advisors.
(Sigal, Steere, Fish, Schoen…. All the
bad guys)
See Weinstein article.
1991 Allen
Steere “Rheumatology News”: Lyme
is perilously close to Fibromyalgia,
CFIDS and Depression.
1992:
Cold Spring Harbor Conferenceà Dattwyler
says, use serial Western Blots and use
IgM to detect infection. Expanding
IgM is evidence of persisting infection.
1992
Allen Steere: Lyme and
Fibromyalgia
1992,
CastleConnolly.com was founded.
1993, with
strain G39/40 (Guilford, CT, Erol
Fikrig) Steere writes THE
OVERDIAGNOSIS OF LYME DISEASE..
The MS, CFIDS, FM, manifestations of
Lyme are now disgarded. You can
only have Lyme, now, if you have a knee,
and meet Dressler/Steere standard for
seroassay.
1993,
Steere had been to Europe, created the
imaginary Dressler/Steere standard,
Steere’s Prospective study in this
report, Accuracy = 39/54 of the
genetically predisposed to react as an
arthritis. 72% of 30 to 35%
= ~23% accurate.
In the
trial, the remaining 76% of the data was
disgarded. NO one has asymptomatic
infection. Vaccination made latent
disease worse. There is another
model for this, with a 19 kD lipoprotein
vaccine for tuberculosis.
The vaccine
actually never worked at all, even in
mice. In vitro studies were
immunofluorescence fof OspA and
Flagellin only. Of course they are
not going to find these spirochetes with
those antibodies BAD DATA, to say
the least.
Other
studies publish by Yale say the same
thing (1994 submissions).
Vaccination did not prevent infection,
just the expression of OspA.
Vaccination/immune response simply
forces a mutation.
Steere’s
standard says that you can’t have an
antibody to OspA to be given a diagnosis
of Lyme disease, but that’s what they
think a vaccine should be. TOTAL
NONSENSE.
1994, March
Connaught trial begins with this
standard, the Company MarDx gets the
work. The blots were probably
unreadable, which Sigal, the principal
investigator, reported in 2000.
They are also unreadable in the monkey
OspA trials.
1994, June,
FDA vaccine meeting. Dattwyler
recommends using serial Western Blots.
This is apparently ignored.
1994,
October: INVITATION to participate in
CDC’s Dearborn Conference (after
Dressler had already been adopted by
Connaught, and in use) Everyone was
ignored except MarDx, who then got all
the business. UCONN says Lyme is
an arthritis also, and was the only
other exception.
1994-5
LymeRIX trials begin.
1998
FDA approves LymeRIX with numerous
provisos.
[Sheller
begins class action.]
1999—I
begin receiving phone calls from
patients who had “Lyme again”
after receiving the vaccine.
I start
campaign to get adverse events reported,
per Dr. Dennis Parenti, at SmithKline
through the VAERS system.
2001, Jan
FDA meeting. By then nearly 1000
adverse events are recorded. I
testify and demonstrate that the
Dressler/Steere standard is bologna ->
Antigenic Variation/ and expansion
(range and or concentration) of the
bands. LymeRIX does not
prevent Asymptomatic Infection, LymeRIX
makes Asymptomatic infection,
SYMPTOMATIC. That’s what
SmithKline’s NEJM data says. (Also
confirmed phenomenon in the
turberculosis lipoprotein vaccines.)
Read Pam
Weintraub’s report.
http://www.whale.to/m/lymerix8.html
Lyme and
tick borne diseases were spun/are
intended to be spun, sell vaccine and
test kits related to vaccines.
There was
no way to qualify a vaccine. So
they lied about everything.
There is no
“Controversy”, as John Connolly created
ALDF.com, and CastleConnolly.com/Managed
Care, to avoid paying for treatment.
Lenny
Sigal, Eugene Shapiro, Robert Schoen and
Janine Evans were FOR HIRE to spin Lyme
disease into a knee. Gave
testimony in court, saying people did
not have “Lyme disease” if they did not
have the arthritis response. And
even if they did, they were “Cured”
although no treatment endpoint was ever
determined and is “Speculative”
according to Dattwyler in the 1989
Infectious Disease reviews.
The
defendants named in this case will be
the experts. It is THEIR data,
which says Lyme is à
1989 Infectious Disease Reviews.
What it was BEFORE ALDF/Managed Care,
Yale, etc, jumped on it.
Now we have
lost 10-15 years.
In that ten
years. Yale’s endowment grew from 2.5
billion to 10.5 billion.
We want
that 8 billion, and we want all the
rights and the royalties from all the
products, We want CastleConnolly sued,
and shut down, and we want several
million from them, and vaccine
manufacturers.
These
people must cease to be funded by the US
government, and we want all the
equipment they bought with their grants.
We will create a TBDs Institute, and
start over because we have no choice.
==============================================
